News | News By Subject | News by Disease News By Date | Search News

Head & neck cancer News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
AstraZeneca PLC (AZN) Faces Another R&D Setback as Plans to File for Early Approval for Cancer Med are Scrapped     11/10/2016
Bristol-Myers Squibb (BMY)’s Opdivo Tagged a Breakthrough by the FDA for Head and Neck Cancer     4/25/2016
Eagle Pharma (EGRX), Teikoku Pharma Win FDA Approval of Docetaxel Injection, First and Only Alcohol-Free Formulation     12/28/2015
Shares Jump as Foamix Pharma (FOMX)'s FDX104 Shows Efficacy in Phase II Study     12/3/2015
ASCO15 EXCLUSIVE: Onxeo Will Run Phase III Trial For Oral Mucositis By End of 2015, CEO Tells BioSpace (DHX)     5/29/2015
Eli Lilly (LLY) Snags North American Rights to Erbitux From Bristol-Myers Squibb (BMY)     4/16/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
AstraZeneca PLC (AZN) Steps Up Push Into Cancer Immunotherapy, Falls Behind Rivals Such As Bristol-Myers Squibb Company (BMY), Merck & Co., Inc. (MRK), And Roche (RHHBY)     7/31/2014
Merck & Co., Inc. (MRK) Immune System-Booster MK3475 Effective In Skin, Lung Cancer     6/2/2014
Navidea Biopharmaceuticals (NAVB) Reports Positive Top-Line Results From Interim Analysis of Lymphoseek     4/4/2013
FDA Approves Bristol-Myers Squibb Company (BMY)'s Erbitux to Treat Late-stage Head and Neck Cancer     11/8/2011
Eli Lilly and Company (LLY) Drops Alimta in Head/Neck Cancer After Failing Phase 3 Trial     10/12/2010
Amgen (AMGN) Announces Top-Line Results of Phase 3 Head and Neck Cancer Trial; Vectibix Fails to Meet Primary Endpoint     8/12/2010

News from Around the Web
Gazing Into The Crystal Ball For Advaxis (ADXS): What To Expect At ASCO 2017     4/7/2017
Stanford University Scientists Look Deeper Into The Body With New Fluorescent Dye     12/29/2015
Compound In Magnolia May Combat Head And Neck Cancers, University of Alabama at Birmingham Study     6/29/2015
Broccoli Sprout May Prevent Head and Neck Cancer, University of Pittsburgh Cancer Institute (UPCI) Study     4/20/2015
How Red Wine Prevents Cancer, University of Colorado Study     12/5/2014
Novel Biomarker For Head And Neck Cancer, Lung Cancer Identified, The Scripps Research Institute Study     4/4/2014
Common Genetic Alteration Found in Head and Neck Cancers May Not be Key to Effective Treatment, Cancer Research Reveals     1/30/2013
Rise in Some Head and Neck Cancers Tied to Oral Sex: University of Wisconsin Study     1/26/2011
Genetic Ancestry: A New Look at Racial Disparities in Head and Neck Cancer, Henry Ford Hospital Study     9/27/2010
Sex Virus Blamed For Rise In Head And Neck Cancers, University Hospital Coventry Study     3/29/2010
Henry Ford Hospital Study Finds 231 New Genes Associated With Head And Neck Cancer     10/5/2009
Curcumin May Inhibit Nicotine-induced Activation Of Head And Neck Cancers, Study Presented At American Academy of Otolaryngology Conference     10/5/2009
University of Pennsylvania School of Medicine Researchers Identify Natural Tumor Suppressor     9/11/2008
Tooth Loss Strongly Linked To Risk Of Esophageal, Head And Neck, And Lung Cancer, Aichi Cancer Center and Nagoya University Study     5/14/2008
Melanoma's Site May Determine Survival; Study Shows Neck, Scalp Melanoma Have Worst Survival Outcomes     4/22/2008

Press Releases
Nanobiotix Expands Its Clinical Development In Head And Neck Cancer And I/O     4/4/2017
Bristol-Myers Squibb (BMY) And Incyte (INCY) To Advance The Combination Of Opdivo (Nivolumab) And Epacadostat Into First-Line Registrational Trials     4/3/2017
Angle: Parsortix Enables Analysis In Head And Neck Cancer     4/3/2017
Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion Recommending Opdivo (Nivolumab) For The Treatment Of Squamous Cell Cancer Of The Head And Neck In Adults Progressing On Or After Platinum-Based Therapy     3/24/2017
CEL-SCI (CVM) Gives Update On Partial Clinical Hold On Phase 3 Head And Neck Cancer Study With Multikine     3/6/2017
Kura Oncology Reports Updated Clinical Activity Data In Ongoing Phase II Trial For Tipifarnib     3/6/2017
Benitec (BLT.AX) Initiates Development Work On Head And Neck Cancer Programs After Executing Collaboration Agreement With Nant Capital     1/30/2017
Soligenix (SNGX) Receives Positive Scientific Advice From The EMA For SGX942 In The Treatment Of Oral Mucositis In Head And Neck Cancer Patients     1/5/2017
Benitec (BLT.AX) In-Licenses Clinical Program For Head And Neck Cancer From NantWorks     12/27/2016
IsoRay (ISR) Announces The Launch Of A Pilot Study Using Intraoperative Placement Of Cesium-131 Permanent Interstitial Brachytherapy In Resectable High Risk Recurrent Head And Neck Cancer By Case Comprehensive Cancer Center     12/21/2016
Soligenix (SNGX) Announces Positive Long-Term Follow-Up Results From Its Phase 2 Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients     12/8/2016
Masonic Cancer Center Release: Immune Response To HPV Impacts Head And Neck Cancer Prognosis     12/8/2016
AstraZeneca PLC (AZN) Catches a Break as the FDA Lifts Hold on Head And Neck Cancer Trials     11/22/2016
CEL-SCI (CVM) Submits Response To FDA In Connection With Partial Clinical Hold On Phase III Clinical Trial     11/21/2016
Inovio Pharma (INO)’s Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses In Tumor Tissue And Peripheral Blood In Patients With HPV-Associated Head And Neck Cancer     11/14/2016

//-->